Cover Image
市場調查報告書

轉移性腎細胞癌:開發平台分析

Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 264087
出版日期 內容資訊 英文 374 Pages
訂單完成後即時交付
價格
Back to Top
轉移性腎細胞癌:開發平台分析 Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016
出版日期: 2016年08月10日 內容資訊: 英文 374 Pages
簡介

轉移性腎細胞癌是指癌細胞侵襲、轉移到腎臟周圍的淋巴結、肺、肝臟、骨骼、腦部等部位的階段。症狀有腹部疼痛、腫脹、背痛、血尿、睪丸周圍靜脈腫(精索靜脈曲張)、體重減輕等,雖然作用比起其他癌症來得低,但治療方法仍以放射線治療、化療為主。

本報告提供轉移性腎細胞癌的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

目錄

簡介

轉移性腎細胞癌概要

治療藥的開發

  • 開發中產品:概要
  • 開發中產品:比較分析

開發中的治療藥:各企業

調查中的治療藥:大學/研究機關別

開發中產品的概要

  • 後期階段的產品
  • 臨床實驗階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

開發中的產品:各企業

調查中的產品:大學/研究機關別

開發治療藥的企業

  • Acceleron Pharma, Inc.
  • Amgen Inc.
  • Argos Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Bayer AG
  • Beta Pharma, Inc.
  • Bionomics Limited
  • Bionovis SA
  • Bristol-Myers Squibb Company
  • Cellceutix Corporation
  • Celldex Therapeutics, Inc.
  • Cerulean Pharma, Inc.
  • Dr. Reddy's Laboratories Limited
  • EirGenix Inc.
  • Eisai
  • Eli Lilly and Company
  • Epirus Biopharmaceuticals, Inc.
  • Exelixis, Inc.
  • Genor BioPharma Co., Ltd.
  • GlaxoSmithKline Plc
  • Hospira, Inc.
  • Immatics Biotechnologies GmbH
  • Immune Design Corp.
  • Immunicum AB
  • Inbiopro Solutions Pvt. Ltd.
  • Mabion SA
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Mycenax Biotech Inc.
  • NewLink Genetics Corporation
  • Novartis AG
  • Oncobiologics, Inc.
  • 小野藥品工業
  • Panacea Biotec Limited
  • Peloton Therapeutics, Inc.
  • Prima BioMed Ltd.
  • Rexahn Pharmaceuticals, Inc.
  • Seattle Genetics, Inc.
  • Sevion Therapeutics, Inc.
  • Syndax Pharmaceuticals, Inc.
  • Tocagen Inc.
  • TVAX Biomedical, Inc.

治療藥的評估

  • 單獨療法的產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

  • AGS-16C3F
  • aldesleukin
  • archexin
  • bevacizumab biosimilar
  • BNC-105
  • BPI-3119
  • cabozantinib s-malate
  • capmatinib
  • Cellular Immunotherapy for Metastatic Renal Cell Carcinoma
  • Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma
  • CRLX-101
  • dalantercept
  • emibetuzumab
  • entinostat
  • flucytosine ER + vocimagene amiretrorepvec
  • G-305
  • IBPM-002BZ
  • IMA-901
  • IMP-321
  • Intuvax
  • ipilimumab
  • KM-3174
  • lenvatinib mesylate
  • LY-2510924
  • Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma
  • nivolumab
  • Orellanine
  • panobinostat
  • pazopanib hydrochloride + pembrolizumab
  • pembrolizumab
  • PT-2385
  • radium Ra 223 dichloride
  • Recombinant Protein for Oncology
  • rocapuldencel-t
  • sapanisertib
  • SGN-CD70A
  • SNX-5422
  • SVN-002
  • trebananib
  • TVI-Kidney-1
  • varlilumab

開發中產品的最新趨勢

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 最新消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8355IDB

Summary

Global Markets Direct's, 'Metastatic Renal Cell Carcinoma - Pipeline Review, H2 2016', provides an overview of the Metastatic Renal Cell Carcinoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Renal Cell Carcinoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Renal Cell Carcinoma and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Renal Cell Carcinoma
  • The report reviews pipeline therapeutics for Metastatic Renal Cell Carcinoma by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Metastatic Renal Cell Carcinoma therapeutics and enlists all their major and minor projects
  • The report assesses Metastatic Renal Cell Carcinoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Metastatic Renal Cell Carcinoma

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Renal Cell Carcinoma
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Metastatic Renal Cell Carcinoma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Renal Cell Carcinoma Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Renal Cell Carcinoma - Overview
    • Pipeline Products for Metastatic Renal Cell Carcinoma - Comparative Analysis
  • Metastatic Renal Cell Carcinoma - Therapeutics under Development by Companies
  • Metastatic Renal Cell Carcinoma - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Renal Cell Carcinoma - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
    • Unknown Stage Products
  • Metastatic Renal Cell Carcinoma - Products under Development by Companies
  • Metastatic Renal Cell Carcinoma - Products under Investigation by Universities/Institutes
  • Metastatic Renal Cell Carcinoma - Companies Involved in Therapeutics Development
    • Acceleron Pharma, Inc.
    • Amgen Inc.
    • Argos Therapeutics, Inc.
    • Astellas Pharma Inc.
    • Bayer AG
    • Bionomics Limited
    • Bionovis SA
    • Bristol-Myers Squibb Company
    • Cellceutix Corporation
    • Celldex Therapeutics, Inc.
    • Cerulean Pharma, Inc.
    • Dr. Reddy's Laboratories Limited
    • EirGenix Inc.
    • Eisai Co., Ltd.
    • Eli Lilly and Company
    • Exelixis, Inc.
    • Gene Techno Science Co., Ltd.
    • Genor BioPharma Co., Ltd.
    • Immune Design Corp.
    • Immunicum AB
    • Incyte Corporation
    • Mabion SA
    • MedImmune, LLC
    • Merck & Co., Inc.
    • Merck KGaA
    • Millennium Pharmaceuticals Inc
    • Mycenax Biotech Inc.
    • NewLink Genetics Corporation
    • Novartis AG
    • Oncobiologics, Inc.
    • Ono Pharmaceutical Co., Ltd.
    • Panacea Biotec Limited
    • Peloton Therapeutics, Inc.
    • Pfizer Inc.
    • Prima BioMed Ltd.
    • Rexahn Pharmaceuticals, Inc.
    • Richter Gedeon Nyrt.
    • Seattle Genetics, Inc.
    • Sevion Therapeutics, Inc.
    • Syndax Pharmaceuticals Inc
    • Taiwan Liposome Company, Ltd.
    • Tocagen Inc.
    • TVAX Biomedical, Inc.
    • Tyrogenex, Inc.
  • Metastatic Renal Cell Carcinoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • AGS-16C3F - Drug Profile
    • avelumab - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • bevacizumab biosimilar - Drug Profile
    • BNC-105 - Drug Profile
    • cabozantinib s-malate - Drug Profile
    • capmatinib - Drug Profile
    • CDX-014 - Drug Profile
    • Cellular Immunotherapy for Metastatic Renal Cell Carcinoma - Drug Profile
    • Cellular Immunotherapy for Metastatic Renal Cell Carcinoma and Melanoma - Drug Profile
    • crizotinib - Drug Profile
    • CRLX-101 - Drug Profile
    • dalantercept - Drug Profile
    • durvalumab - Drug Profile
    • emibetuzumab - Drug Profile
    • entinostat - Drug Profile
    • flucytosine ER + vocimagene amiretrorepvec - Drug Profile
    • G-305 - Drug Profile
    • IMP-321 - Drug Profile
    • INCAGN-1876 - Drug Profile
    • Intuvax - Drug Profile
    • ipilimumab - Drug Profile
    • KM-3174 - Drug Profile
    • lenvatinib mesylate - Drug Profile
    • LY-2510924 - Drug Profile
    • Monoclonal Antibody Conjugate to Target G250 Antigen for Renal Cell Carcinoma - Drug Profile
    • nivolumab - Drug Profile
    • Orellanine - Drug Profile
    • panobinostat - Drug Profile
    • pazopanib hydrochloride + pembrolizumab - Drug Profile
    • pembrolizumab - Drug Profile
    • PT-2385 - Drug Profile
    • radium Ra 223 dichloride - Drug Profile
    • Recombinant Protein for Oncology - Drug Profile
    • rocapuldencel-T - Drug Profile
    • RX-0201 - Drug Profile
    • sapanisertib - Drug Profile
    • SGN-CD70A - Drug Profile
    • Small Molecules to Inhibit SCD1 for Metastatic Renal Cell Carcinoma - Drug Profile
    • SNX-5422 - Drug Profile
    • SVN-002 - Drug Profile
    • TLC-388 - Drug Profile
    • trebananib - Drug Profile
    • TVI-Kidney-1 - Drug Profile
    • varlilumab - Drug Profile
    • X-82 - Drug Profile
  • Metastatic Renal Cell Carcinoma - Dormant Projects
  • Metastatic Renal Cell Carcinoma - Discontinued Products
  • Metastatic Renal Cell Carcinoma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016
  • Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Development by Companies, H2 2016 (Contd..1)
  • Number of Products under Development by Companies, H2 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Comparative Analysis by Unknown Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Development by Companies, H2 2016 (Contd..2)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Acceleron Pharma, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Amgen Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Argos Therapeutics, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Astellas Pharma Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Bayer AG, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Bionomics Limited, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Bionovis SA, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Bristol-Myers Squibb Company, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Cellceutix Corporation, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Celldex Therapeutics, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Cerulean Pharma, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Dr. Reddy's Laboratories Limited, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by EirGenix Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Eisai Co., Ltd., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Eli Lilly and Company, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Exelixis, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Gene Techno Science Co., Ltd., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Genor BioPharma Co., Ltd., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Immune Design Corp., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Immunicum AB, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Incyte Corporation, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Mabion SA, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by MedImmune, LLC, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Merck & Co., Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Merck KGaA, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Millennium Pharmaceuticals Inc, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Mycenax Biotech Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by NewLink Genetics Corporation, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Novartis AG, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Oncobiologics, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Panacea Biotec Limited, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Peloton Therapeutics, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Pfizer Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Prima BioMed Ltd., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Richter Gedeon Nyrt., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Seattle Genetics, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Sevion Therapeutics, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Syndax Pharmaceuticals Inc, H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Taiwan Liposome Company, Ltd., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Tocagen Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by TVAX Biomedical, Inc., H2 2016
  • Metastatic Renal Cell Carcinoma - Pipeline by Tyrogenex, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Metastatic Renal Cell Carcinoma - Dormant Projects, H2 2016
  • Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..1), H2 2016
  • Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..2), H2 2016
  • Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..3), H2 2016
  • Metastatic Renal Cell Carcinoma - Dormant Projects (Contd..4), H2 2016
  • Metastatic Renal Cell Carcinoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Metastatic Renal Cell Carcinoma, H2 2016
  • Number of Products under Development for Metastatic Renal Cell Carcinoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Top 10 Molecule Types, H2 2016
  • Number of Products by Stage and Top 10 Molecule Types, H2 2016
Back to Top